- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00246103
Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a Phase I dose escalation trial with escalating doses of Valproic acid and one dose escalation step of epirubicin. VPA will be escalated starting at a dose that is recommended for use as an anti-convulsant or to treat migraine headaches. Recommended concentrations for seizure control is 15-60 mg/kg. Pharmacokinetic studies from healthy volunteers and patients suggested a linear increase in plasma concentrations. A daily dosing of 16 mg/kg divalproex (delayed-release VPA) resulted in a peak VPA plasma concentration of 127 μg/ml (~0.9 mM) 27. The recommended Phase II dose of VPA was 60 mg/kg/d when given by a one-hour intravenous infusion twice daily for 5 days every three weeks.
Synergistic activity between VPA and epirubicin has been observed at 0.5 mM of VPA in our preclinical laboratory studies. Patients will receive an intravenous loading dose of VPA followed by divalproex in two daily doses for 5 doses. The loading dose of VPA will avoid a delay in peak plasma concentrations and excessive nausea. Epirubicin will be given by infusion on day 3 after the last dose of divalproex.
Once the MTD for this two drug regimen has been determined, the maximum tolerated dose will be determined as part of the FEC regimen (5-fluorouracil, epirubicin and cyclophosphamide).
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Florida
-
Tampa, Florida, Forente stater, 33612
- H. Lee Moffitt Cancer Center & Research Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients must have cytologically/histologically documented solid tumor malignancies
- Age > 18 years old
- Patients must have ECOG performance status 0-2
- Patients must be able to give informed consent and able to follow guidelines given in the study
- The patient has no major impairment of hematological function, as defined by the following laboratory parameters: WBC >3.0x109/L; ANC > 1.5 x 109/L; Hgb >9.0g/dL; PLT >100x109/L (untransfused). Red blood cell transfusions and repeat evaluations for study entry are allowed
- All patients of reproductive potential must use an effective method of contraception during the study and six months following termination of treatment. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to female patients who are older than 50 years and have not had a menstrual cycle in more than one year.
- Patients must have measurable or evaluable disease by staging studies performed within 4 weeks of enrollment (evaluable disease refers to ovarian cancer with an elevated CA-125 or prostate cancer with elevated PSA only)
- Once MTD for VPA and epirubicin is reached, the trial will be limited to patients with breast cancer
- At the MTD for VPA and FEC MTD for the trial will be expanded to 15 patients with advanced (inflammatory, Stage >IIIB or regional stage IV) or metastatic breast cancer.
- Patients must have biopsiable disease and be willing to undergo pre and post-VPA biopsies in cycle 1; Patients must have measurable disease, Patients from the last cohort may be included if they were biopsied
Exclusion Criteria:
- Patients may not have had cumulative anthracycline exposure greater than doxorubicin 300 mg/m2 or epirubicin 600 mg/m2.
- Patients must not have evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study entry.
- Patients must have adequate renal and normal hepatic function (creatinine < 1.5 x upper limit of normal (ULN), bilirubin and SGOT (AST), SGPT (ALT) within 1.5 x the upper institutional normal limits) obtained within 4 weeks prior to registration.
- Pregnant and breast feeding women are excluded from the study because effects on the fetus are unknown and there may be a risk of increased fetal wastage.
- Women of childbearing age must have a negative pregnancy test and be willing to use a highly effective method of contraception. Men who are sexually active must also be willing to use an accepted and effective method of contraception.
- Patients taking anti-arrhythmic medication or with a history of cardiac failure or with ejection fraction £ 50 % are excluded. Patients with a history of long QT syndrome are excluded from study. Patients with a history of ventricular tachycardia or fibrillation are also excluded. Patients must have normal sinus rhythm and normal PR and QT intervals on EKG.
- Patients with uncontrolled CNS metastasis or a history of seizures are excluded. Patients with stable CNS metastasis (either surgically resected, treated with gamma knife or stable for 3 months following WBRT are eligible)
- Patients with stable brain metastases will need an MRI within 4 weeks prior to start of therapy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Dose Escalation and Possible Expansion
Escalating doses of Valproic acid and one dose escalation step of epirubicin.
Participants with breast cancer treated at the maximum tolerated dose, will also be treated with 5-fluorouracil and Cyclophosphamide.
|
Beginning Dose, Level 1: 15 mg/kg/day.
Andre navn:
Beginning Dose, Level 1: 75 mg/m^2.
Andre navn:
For breast cancer participants treated at MTD of Valproic acid and Epirubicin: 5-fluorouracil 500 mg/m^2.
Andre navn:
For breast cancer participants treated at MTD of Valproic acid and Epirubicin: cyclophosphamide 500 mg/m^2.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Maximum Tolerated Dose (MTD)
Tidsramme: Up to 2 months
|
MTD of Valproic acid in combination with Epirubicin.
The maximum tolerated dose (MTD) will be defined as the highest dose level at which less than 2 out of 6 patients (<33%) experience DLT in Cycle 1.
A dose limiting toxicity (DLT) will be defined as any one of the specific adverse events (AEs) outlined in the protocol, occurring during Cycle 1 when considered related to therapy that is part of this study.
|
Up to 2 months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Pharmacokinetic Profile
Tidsramme: 6 months
|
To determine the pharmacokinetic profile of valproic acid and epirubicin in this combination.
|
6 months
|
VPA effects on Histone Acetylation
Tidsramme: 6 months
|
To determine VPA effects on histone acetylation in peripheral blood mononuclear cells and VPA effects on histone acetylation and epirubicin induced DNA damage in biopsied tumors.
|
6 months
|
MTD for VPA and Epirubicin in Combination with 5-fluorouracil and Cyclophosphamide
Tidsramme: 6 months
|
To determine the MTD for VPA and epirubicin in combination with 5-fluorouracil and cyclophosphamide commonly known as a regimen called FEC100.
|
6 months
|
Utility of Topo IIα and IIβ as Predictive Factors for Response
Tidsramme: 6 months
|
To determine the utility of topo IIα and IIβ as predictive factors for response and their modulation as drug targets in patients with biopsied tumors and to document any responses to this combination.
|
6 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Adil Daud, MD, H. Lee Moffitt Cancer Center and Research Institute
- Hovedetterforsker: Pamela Munster, MD, H. Lee Moffitt Cancer Center and Research Institute
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Neoplasmer
- Fysiologiske effekter av legemidler
- Nevrotransmittere agenter
- Molekylære mekanismer for farmakologisk virkning
- Sentralnervesystemdepressiva
- Enzymhemmere
- Antirevmatiske midler
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Antineoplastiske midler, Alkylering
- Alkyleringsmidler
- Myeloablative agonister
- Topoisomerase II-hemmere
- Topoisomerasehemmere
- Beroligende midler
- Psykotropiske stoffer
- GABA-agenter
- Antikonvulsiva
- Antimaniske midler
- Antibiotika, antineoplastisk
- Cyklofosfamid
- Fluorouracil
- Epirubicin
- Valproinsyre
Andre studie-ID-numre
- MCC-13693
- USFIRB#101881
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Neoplasmer, avansert
-
Guangzhou First People's HospitalFullført
-
Providence Health & ServicesTilgjengeligKRAS G12V Mutant Advanced Epithelial Cancers
-
Shanghai Pudong HospitalUTC Therapeutics Inc.TilbaketrukketMesothelin-positive Advanced Refractory Solid TumorsKina
-
Novartis PharmaceuticalsFullførtcMET Dysegulation Advanced Solid TumorsØsterrike, Danmark, Sverige, Storbritannia, Spania, Tyskland, Nederland, Forente stater
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRekrutteringKRAS G12C Mutant Advanced Solid TumorsKina
-
AZ-VUBAstraZeneca; Kom Op Tegen KankerRekrutteringAdvanced Cancers Harboring Mutations in HRGBelgia
-
AmgenAktiv, ikke rekrutterendeKRAS p.G12C Mutant Advanced Solid TumorsForente stater, Frankrike, Canada, Spania, Belgia, Korea, Republikken, Østerrike, Australia, Ungarn, Hellas, Tyskland, Japan, Romania, Sveits, Brasil, Portugal
-
Agenus Inc.FullførtAvansert solid kreft | Advanced Solid Cancers Refractory to PD-1Forente stater
-
Yongchang ZhangRekrutteringHER2 Insertion Mutation Positive Advanced NSCLCKina
-
Extremity MedicalRekrutteringArtrose | Inflammatorisk leddgikt | Karpaltunnelsyndrom (CTS) | Posttraumatisk leddgikt | Scapholunate Advanced Collapse (SLAC) | Scapholunate Crystalline Advanced Collapse (SCAC) | Scaphoid, Trapesium og Trapesoid Advanced Collapse (STTAC) | Kienbocks sykdom hos voksne | Radial Malunion | Ulnar Translokasjon og andre forholdForente stater
Kliniske studier på Valproic acid
-
Joliet Center for Clinical ResearchAbbottFullførtStemningsforstyrrelseForente stater
-
Ultragenyx Pharmaceutical IncFullførtHereditary Inclusion Body Myopati (HIBM)Forente stater
-
National University of Ireland, Galway, IrelandStanley Medical Research InstituteFullførtBipolar depresjonIrland
-
University of California, Los AngelesFullførtGlukoseintoleranse | Overvektige | Pre-diabetesForente stater
-
Becton, Dickinson and CompanyAktiv, ikke rekrutterende
-
Hadassah Medical OrganizationFullført
-
BayerFullførtKontrastmedierForente stater, Tyskland, Italia, Korea, Republikken, Østerrike, Thailand, Australia, Spania, Storbritannia
-
Ultragenyx Pharmaceutical IncAvsluttetArvelig inkluderingskroppsmyopati | GNE Myopati | Inkluderingskroppsmyopati 2 | Distal myopati med kantede vakuoler | Distal myopati, Nonaka Type | Quadriceps sparende myopatiCanada, Forente stater, Bulgaria
-
McMaster UniversityAjinomoto USA, INC.FullførtPsykologiske fenomener: Sentral tretthetCanada
-
Ultragenyx Pharmaceutical IncAvsluttetArvelig inkluderingskroppsmyopati | GNE Myopati | Distal myopati med kantede vakuoler | Distal myopati, Nonaka Type | Quadriceps sparende myopatiForente stater, Canada, Storbritannia, Israel, Italia, Bulgaria, Frankrike